Synonym
Nevirapine-d3; Nevirapine d3; Nevirapined3; 12-D3NVP; 12 D3NVP; 12D3NVP
IUPAC/Chemical Name
2-cyclopropyl-7-(trideuteriomethyl)-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
InChi Key
NQDJXKOVJZTUJA-FIBGUPNXSA-N
InChi Code
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)/i1D3
SMILES Code
O=C1NC2=C(C([2H])([2H])[2H])C=CN=C2N(C3CC3)C4=C1C=CC=N4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
269.32
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Notter J, Bregenzer A, Vernazza P, Kahlert CR. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? Swiss Med Wkly. 2019 Apr 24;149:w20053. doi: 10.4414/smw.2019.20053. PMID: 31017649.
2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Nevirapine. 2014 Feb 2. PMID: 31644202.
3: Neary M, Chappell CA, Scarsi KK, Nakalema S, Matovu J, Achilles SL, Chen BA, Siccardi M, Owen A, Lamorde M. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. J Antimicrob Chemother. 2019 Oct 1;74(10):3003-3010. doi: 10.1093/jac/dkz298. PMID: 31299074; PMCID: PMC6753484.
4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Nevirapine. 2020 Jan 20. PMID: 30000595.
5: Rehman N, Nguyen H. Nevirapine. 2020 Feb 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32119364.
6: Popovic M, Shenton JM, Chen J, Baban A, Tharmanathan T, Mannargudi B, Abdulla D, Uetrecht JP. Nevirapine hypersensitivity. Handb Exp Pharmacol. 2010;(196):437-51. doi: 10.1007/978-3-642-00663-0_15. PMID: 20020271.
7: Milinkovic A, Martínez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004 Jun;2(3):367-73. doi: 10.1586/14787210.2.3.367. PMID: 15482202.
8: Taiwo BO. Nevirapine toxicity. Int J STD AIDS. 2006 Jun;17(6):364-9; quiz 370. doi: 10.1258/095646206777323346. PMID: 16734954.
9: Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT; IMPAACT P1079 protocol team. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017 Oct 24;12(10):e0186589. doi: 10.1371/journal.pone.0186589. PMID: 29065172; PMCID: PMC5655345.
10: Awodele O, Popoola T, Rotimi K, Ikumawoyi V, Okunowo W. Antioxidant modulation of nevirapine induced hepatotoxicity in rats. Interdiscip Toxicol. 2015 Mar;8(1):8-14. doi: 10.1515/intox-2015-0002. PMID: 27486354; PMCID: PMC4961920.
